Kodiak Sciences Inc. (KOD)
| Market Cap | 7.41B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.13M |
| Shares Out | 45.12M |
| EPS (ttm) | -2.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $145.91 |
| Previous Close | $155.89 |
| Change ($) | -9.98 |
| Change (%) | -6.40% |
| Day's Open | 156.81 |
| Day's Range | 144.52 - 158.13 |
| Day's Volume | 284,930 |
| 52-Week Range | 38.18 - 164.47 |
PALO ALTO, Calif., Jan. 5, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeu...
PALO ALTO, Calif., Nov. 20, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...
PALO ALTO, Calif., Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...
PALO ALTO, Calif., Nov. 12, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...
PALO ALTO, Calif., Nov. 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therape...
Kodiak Sciences (KOD) reports wider-than-expected loss in the third quarter of 2020. The company is progressing well with the development of its lead pipeline candidate KSI-301.
PALO ALTO, Calif., Nov. 9, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeu...
Biotech companies with IPOs of at least $50 million in the past three years have averaged an increase in share price of more than 42%. Gainers outpaced decliners by a ratio of two to one, acco...
VANCOUVER, British Columbia & PALO ALTO, Calif.--(BUSINESS WIRE)---- $KOD #AbCellera--AbCellera and Kodiak Sciences Inc. (Nasdaq: KOD), today announced a new partnership to generate therapeuti...
PALO ALTO, Calif., Oct. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeu...
The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.
Insider buying can be an encouraging signal for potential investors when markets are near all-time highs.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.
PALO ALTO, Calif., Aug. 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc.
PALO ALTO, Calif., July 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc.
PALO ALTO, Calif., July 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-preval...
Kodiak Sciences (KOD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Kodiak Sciences Inc. (KOD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
As of late, it has definitely been a great time to be an investor in Kodiak Sciences
Kodiak Sciences Inc. (KOD) CEO Victor Perlroth on Q1 2020 Results - Earnings Call Transcript
These are the small cap stocks with the best value, fastest growth, and most momentum for May.
These three developmental-stage pharma stocks are attracting some of the smartest investors right now.
Coronavirus Has Presented A Buying Opportunity In Kodiak Sciences
These are the biotechnology stocks with the best value, fastest growth, and most momentum for Q2 2020.
Kodiak Sciences Inc’s (NASDAQ: KOD) main drug candidate, KSI-301, highlights the company’s focus on innovation in a dynamic treatment landscape, according to Goldman Sachs.
After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in th...
Seven biotechs led the way.
Kodiak Sciences: Stock That Skyrocketed In December
These stocks have soared 935% or more this year. Can they keep the momentum going?
Here's why these drugmaker stocks are the year's top performers.
Is (KOD) Outperforming Other Medical Stocks This Year?
Does Kodiak Sciences Inc. (KOD) have what it takes to be a top stock pick for momentum investors?
Kodiak Sciences Fully Funded And Ready To Potentially Change Wet-AMD Treatment
Helping people stricken with illness can be richly rewarding in more ways than one.
These clinical-stage biotech stocks have delivered eye-popping gains in 2019, but what about the road ahead?
As of late, it has definitely been a great time to be an investor in Kodiak Sciences.
Kodiak Sciences Inc. (KOD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
These stocks helped lead the markets higher.
Momentum continues from the drugmaker's royalty deal announced earlier this week despite a big public stock offering.
Kodiak Sciences (KOD) news about the company selling royalty rights for $225 million has KOD stock heading higher on Monday.
Investors are excited about a big royalty deal for the biotech's lead pipeline candidate.
Inside the best performing stocks of the Russell 2000 ETF.
Despite soaring already, these biotech stocks aren't finished climbing.
Kodiak Sciences, Inc. (KOD) CEO Victor Perlroth on Q3 2019 Results - Earnings Call Transcript
Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
About KOD
Kodiak Sciences, a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The c... [Read more...]
| Industry Biotechnology | IPO Date Oct 4, 2018 |
| CEO Dr. Victor Perlroth | Employees 62 |
| Stock Exchange NASDAQ | Ticker Symbol KOD |
Analyst Forecasts
According to 11 analysts, the average rating for KOD stock is "Buy." The 12-month stock price forecast is 125.18, which is a decrease of -14.21% from the latest price.